Anticipate a potential shareholder capital return in Q3 2026 after receipt of Moderna settlement proceeds. Monitor appellate developments on Section 1498, which could unlock significant additional value. Clinical progress in HBV functional cures supports long-term upside in imdusiran; watch for upcoming trial readouts or partnership interest.
Price Chart
Executive Summary
Arbutus Biopharma reported improved financials for 2025 with a narrowed net loss and strong cash position, driven by cost reductions and revenue recognition from a concluded partnership. The company also announced a $950 million noncontingent settlement payment from Moderna related to LNP patent litigation, with potential for an additional $1.3 billion contingent on a legal ruling. Two more patients achieved functional cure in its HBV trial, bringing the total to 10, reinforcing clinical momentum.
Key Financial Metrics
Key Facts
- Arbutus will receive $950 million from Moderna in July 2026 as part of a global patent settlement, with a 20% share ($190 million) going directly to Arbutus after litigation cost deductions.
- Additional $1.3 billion contingent payment from Moderna is pending a U.S. appellate ruling on Section 1498; Arbutus stands to gain a portion via its 16% stake in Genevant and licensing terms.
- Two additional patients achieved functional cure in imdusiran Phase 2a trials, bringing total to 10, with six sustaining cure for over two years.
- Total revenue increased to $14.1 million in 2025 from $6.2 million in 2024, primarily due to recognition of deferred revenue from Qilu partnership termination.
- Net loss narrowed to $33.5 million in 2025 from $69.9 million in 2024, with R&D expenses cut by over 50% due to restructuring.
- Cash, cash equivalents, and marketable securities totaled $91.5 million as of December 31, 2025, down from $122.6 million, but cash burn improved significantly.
Financial Impact
$190 million noncontingent cash inflow expected in Q3 2026 (20% of $950M), with potential for additional upside from contingent payment and Genevant equity stake; revenue up 127% YoY, net loss cut by 52%.
Risk Factors
- The $1.3 billion contingent payment from Moderna depends on a favorable appellate ruling on Section 1498, which is uncertain and could be denied.
- Arbutus' future value remains highly dependent on clinical success of imdusiran and AB-101, which are still in development and may not achieve regulatory approval.
- Downward revenue trend from Alnylam royalties due to declining ONPATTRO sales may continue, reducing near-term licensing income.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260272 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | 8-K | $5.21 $5.00 | ▼ −4.03% | ▼ −3.50% | $4.45 (−14.59%) |
Aug 15, 2026 6w ago | Institutional Cluster | $4.71 $5.06 | ▲ +7.43% | ▲ +9.41% | $4.45 (−5.52%) |
Aug 12, 2026 7w ago | 8-K | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Aug 12, 2026 7w ago | Press Release | $4.59 $5.12 | ▲ +11.55% | ▲ +13.44% | $4.45 (−3.05%) |
Jul 16, 2026 11w ago | 8-K | $4.74 $4.58 | ▼ −3.38% | ▼ −6.99% | $4.45 (−6.12%) |
Jun 12, 2026 16w ago | Institutional Cluster | $4.26 $4.80 | ▲ +12.68% | ▲ +10.90% | $4.45 (+4.46%) |
May 13, 2026 20w ago | 8-K | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
May 13, 2026 20w ago | Press Release | $4.31 $4.29 | ▼ −0.46% | ▲ +0.15% | $4.45 (+3.25%) |
Apr 15, 2026 24w ago | 8-K | $4.48 $4.31 | ▼ −3.79% | ▼ −9.84% | $4.45 (−0.67%) |
Mar 23, 2026 27w ago | Press Release | $4.42 $4.43 | ▲ +0.23% | ▼ −7.19% | $4.45 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access